Rare (RARE) news

BUZZ-Ultragenyx profits from selling a U.S. FDA voucher worth $210 millions

October 7 - ** Pharmaceutical company Ultragenyx Pharmaceutical (RARE.O) shares rose 2.8% to $14.87 ** Ultragenyx agreed to sell an FDA priority review voucher for $210 million in cash ** The company received the voucher after FDA approval of its drug Genglycos (link) for treating Glycogen Storage Disease Type Ia (also known as von Gierke disease) ** According to the licensing agreement, upon completion of the transaction, Ultragenyx will pay 20% of the voucher sale proceeds to the U.S. National Institutes of Health ** In response to Reuters’ inquiry about the buyer, Ultragenyx has not yet replied ** The recommended retail price per patient for Genglycos in the U.S. is $2.7 million ** As of the previous trading day’s close, the stock had fallen about 35% year to date (In order to facilitate non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be erroneous or lack required context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for the convenience of readers. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation tools.)

Ultragenyx agrees to sell rare pediatric disease priority review voucher for $210 million

Ultragenyx entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 210 million. The voucher was awarded on FDA clearance of GENGLYCOS (DTX401) for glycogen storage disease type Ia. Proceeds are expected to provide non-dilutive funding for pipeline development, supporting the company’s profitability plans. Closing depends on customary conditions, including expiration of the Hart-Scott-Rodino waiting period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070830PRIMZONEFULLFEED9841089) on October 07, 2026, and is solely responsible for the information contained therein.

Chinese Yuan: Strengthens into US–China summit – Societe Generale

MP Materials adjusted profit beats Street on rising rare earths sales

France convenes G7 on critical minerals to curb China’s grip

China tightens grip on rare earths with strict enforcement rules

XRP volume jumps 7x as rare bull switch emerges

U.S. stocks move: U.S. rare earth concept stocks generally rise, Cleveland-Cliffs up over 9%

US Stocks Movement: USA Rare Earth rises over 8%, leading the rare earth sector

Lynas Rare Earths more than doubles third-quarter revenue

China’s rare earth magnet exports fall 1.6% in March

RARE (SuperRare) 24-hour volatility at 62.0%: Trading volume surges 1500%, leading to CEX pump and subsequent pullback

RARE (SuperRare) fluctuates 55.2% in 24 hours: trading volume surges 15 times, triggering intense pumping

RARE (SuperRare) fluctuated 64.1% in 24 hours: trading volume surged over 15 times, driving violent price swings

RARE (SuperRare) 24-hour amplitude reaches 41.7%: trading volume increases but with no clear event driver

U.S. rare earth concept stocks surged across the board

Greenland’s actions ‘amount to direct expropriation’, says Energy Transition Minerals MD

Rare Earths Americas applies for US IPO

ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules

Energy Transition Minerals faces likely licence renewal rejection for Greenland project

Ethereum Derivatives Market Sees Rare Net Buying for First Time Since 2023 Bear Market

Australia blocks Hong Kong investor’s voting rights in Northern Minerals

Arafura Rare Earths secures $159 million to boost Nolans project

US to commit $250 million toward supply chain investment fund

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

Beyond mining: Oklahoma bets on refining to anchor US critical minerals supply chain

Critical minerals drive new commodity supercycle: Sprott

Trump Intends To Use AI For Pricing Critical Minerals

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx to Participate at Investor Conferences in March